Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) FCF Margin (2016 - 2025)

China Pharma Holdings' FCF Margin history spans 16 years, with the latest figure at 5.98% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1865.0% year-over-year to 5.98%; the TTM value through Dec 2025 reached 0.26%, up 945.0%, while the annual FY2025 figure was 0.26%, 1007.0% up from the prior year.
  • FCF Margin reached 5.98% in Q4 2025 per CPHI's latest filing, up from 31.42% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 52.11% in Q3 2023 to a low of 72.04% in Q1 2023.
  • Average FCF Margin over 5 years is 8.95%, with a median of 7.48% recorded in 2021.
  • Peak YoY movement for FCF Margin: plummeted -5955bps in 2022, then skyrocketed 5381bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 7.1% in 2021, then surged by 395bps to 20.95% in 2022, then plummeted by -106bps to 1.25% in 2023, then soared by 2071bps to 24.62% in 2024, then plummeted by -76bps to 5.98% in 2025.
  • Per Business Quant, the three most recent readings for CPHI's FCF Margin are 5.98% (Q4 2025), 31.42% (Q3 2025), and 28.6% (Q2 2025).